Amedisys to Host Complimentary Webinar for Health Care Leaders on Managing Diabetes in the Frail, Multi-Morbid Patient

BATON ROUGE, La.--(BUSINESS WIRE)--A representative from Baton Rouge-based Amedisys, Inc. will be joined by two other national health care leaders in a complimentary webinar that will provide insight on the latest ADA Standards for diabetes care. The webinar will be held on Tuesday, September 27, from 11:00 a.m. – 12:00 p.m. CST. Amedisys (NASDAQ: AMED) is a leading home health care and hospice company, providing care to more than 35,000 patients nationwide every day.

“Managing Diabetes in the Frail, Multi-Morbid Patient”

The webinar, titled “Managing Diabetes in the Frail, Multi-Morbid Patient,” will cover details and answer questions regarding the latest ADA Standards for diabetes care. These standards confirm the findings of multiple trials and systematic reviews which state that for some populations, particularly frail elderly patients who may be at the end of life, tight control of glycosolated hemoglobin does not prolong life, decrease hospital admissions, decrease cardiovascular complications, or improve quality of life. In fact, such tight control may render these frail patients at higher risk for falls and other accidents.

The webinar features Dr. Michael Fleming, Amedisys Chief Medical Officer; Dr. Peter Boling, MD, Director of Longterm Care and Geriatrics at Virginia Commonwealth University, Medical College of Virginia; and Dr. John Buse, MD, PhD, Associate Professor of Medicine, Chief, Division of General Internal Medicine and Clinical Epidemiology, Director, Diabetes Care Center, University of North Carolina School of Medicine Chapel Hill, N.C.

“Frail, elderly diabetic patients with multiple chronic diseases present a significant management challenge recent studies have commented,” said Michael Fleming, MD, FAAFP and Chief Medical Officer for Amedisys. “Our panel will discuss the latest management recommendations for achieving the best outcomes for these patients,” continued Fleming.

Those interested in attending the webinar can register at http://www.antidotecme.com/diabetes/. The webinar is supported through an educational grant from Amedisys and is planned and implemented in accordance with the policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and Amedisys. The webinar is approved for AMA PRA Category 1 Credit™ and American Academy of Family Physicians Prescribed credit.

About Amedisys:

Amedisys, Inc. (NASDAQ: AMED) is the nation’s leading health care company focused on bringing home the continuum of care. Each day Amedisys delivers personalized health care services to more than 35,000 individual patients and their families, in the comfort of patients’ homes. Amedisys has two divisions, home health care and hospice, and employs more than 16,000 skilled clinicians across the country. The Company’s state-of-the-art advanced chronic care management programs and leading-edge technology enable it to deliver quality care based upon the latest evidence-based best practices. Amedisys is a recognized innovator, being the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry’s first-ever nationwide Care Transitions program. Amedisys Care Transitions is designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient’s home health plan of care. For more information about the Company, please visit: www.amedisys.com.

When included in this press release, words like "believes," "belief," "expects," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, adverse effects of a failure of the Federal government to fund government programs in which we participate, such as Medicare or Medicaid, adverse effects of a possible delay in the Federal budget process or a Federal government shutdown, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, changes in or developments with respect to any litigation or investigations relating to the Company, including the United States Senate Committee on Finance inquiry, the SEC investigation and the U.S. Department of Justice Civil Investigative Demand and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding the Company is routinely posted on and accessible on the “Investor Relations” subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We will also use our website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (“SEC”) disclosing the same information. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Nominating and Corporate Governance and Quality of Care Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Corporate Governance”).